n-methylisoindigotin has been researched along with hydroxyurea in 2 studies
*Hydroxyurea: An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. [MeSH]
*Hydroxyurea: An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. [MeSH]
| Studies (n-methylisoindigotin) | Trials (n-methylisoindigotin) | Recent Studies (post-2010) (n-methylisoindigotin) | Studies (hydroxyurea) | Trials (hydroxyurea) | Recent Studies (post-2010) (hydroxyurea) |
|---|---|---|---|---|---|
| 34 | 0 | 11 | 8,969 | 741 | 2,156 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, Y; Liu, B; Qian, L; Xiao, Z | 2 |
1 review(s) available for n-methylisoindigotin and hydroxyurea
| Article | Year |
|---|---|
Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Blast Crisis; China; Dose-Response Relationship, Drug; Humans; Hydroxyurea; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Chemical; Time Factors; Treatment Outcome | 2002 |
1 other study(ies) available for n-methylisoindigotin and hydroxyurea
| Article | Year |
|---|---|
Meisoindigo for the treatment of chronic myelogenous leukaemia.
Topics: Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Hydroxyurea; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nucleic Acid Synthesis Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies | 2000 |